Clinical trial · no report yet · Phase 3
DeLLphi-312
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
- NCT07005128 ↗
- Active not recruiting
- Amgen
- 17 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 5 | |
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer
- Interventions
- Tarlatamab; Durvalumab; Carboplatin; Etoposide
- Arms
- Tarlatamab + Durvalumab + Carboplatin + Etoposide · Experimental
- Durvalumab + Carboplatin + Etoposide · Active comparator
- Enrollment
- 350
- Primary outcomes
- Overall Survival (OS)
- Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)
- Sponsor
- Amgen with AstraZeneca
- Start
- Aug 18, 2025
- Primary completion
- Jan 4, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07005128 · updated Sep 8, 2026